One study with hundred patients with mild, moderate, and severe COVID-19 showed that, after six months, NfL concentrations had normalized, with no persisting group differences, and they found no correlation between persistent neurological symptoms and CNS injury biomarkers in the acute phase [89]. The gene discussed is NEFL; the disease is COVID-19.